




RealRate

PHARMACEUTICAL 2021

Adial Pharmaceuticals INC
Rank 334 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Adial Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adial Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 15% points. The greatest weakness of Adial Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 120% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	5,136
Cost of Goods Sold	0
Intangible Assets	5.6
Liabilities, Current	1,505
Liabilities, Non-Current	0
Other Assets	350
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	35
Other Revenues	0
Property and Equipment	0
Research and Development	5,853
Selling, General and Administrative Expense	5,075

Output Variable	Value in 1000 USD
Assets	5,491
Liabilities	1,505
Expenses	10,928
Revenues	0
Stockholders Equity	3,986
Net Income	-10,893
Comprehensive Net Income	-10,893
BaseVar	8,980
ECR before Limited Liability	-63%
Economic Capital Ratio	137%